以微核酸-196a 分子及微核酸-196b分子運用於偵測口腔癌的方法

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

101118648

專利證號

I 461540

專利獲證名稱

以微核酸-196a 分子及微核酸-196b分子運用於偵測口腔癌的方法

專利所屬機關 (申請機關)

長庚大學

獲證日期

2014/11/21

技術說明

口腔癌是世界十大癌症之ㄧ，但目前並無適當之分子腫瘤標誌，可應用於口腔癌的臨床偵測。本研究中，我們以六株口腔癌細胞株及四株口腔正常黏膜細胞，進行470個微核酸(microRNA, miRNA)之篩檢，結果發現其中23個最具表現差異，含微核酸-196。研究發現，微核酸-196具促進細胞移形侵襲能力，且在癌組織中有過高表現，為一致癌性微核酸(oncomir)。利用反轉錄即時定量聚合脢反應技術(RT-qPCR)，偵測微核酸-196在口腔癌病患及正常志願者血漿的表現量，發現無論微核酸-196a或微核酸-196b均較之正常者有明顯之高度表現(p<0.0001)，以Receiver Operational Curve (ROC)分析得知，微核酸-196a及微核酸-196b的Area Under Curve (AUC)值均高於0.90，(分別為0.934與0.902)，其偵測敏感度達90%，專一性達85%，表示微核酸-196分子具有良好的口腔癌偵測能力，因此進行專利申請之。 Oral cancer is one of ten leading cancers worldwide, but short of clinical useful tumor biomarker for detection. MiR-196s were found significantly differential expressions between normal and cancer cells and promoted cellular migration and invasion. MiR-196s was up-regulated in the cancer tissues compared to adjacent normal counterparts (P<0.001). To assess potential application, miR-196 was determined in the plasma samples from 33 normal individuals and 54 oral cancer patients. It showed that miR-196s was significantly elevated in oral cancer patients (p<0.0001). Using receiver operational curve (ROC) analysis, miR-196s yielded an area under curve (AUC) over 0.90 (0.938 and 0.942 for miR-196a and 196b, respectively). The detection sensitivity and specificity were approximately 90% and 84%, suggesting miR-196 possessing a high potential to discriminate oral cancer patients. We conclude that miR-196s could serve as a biomarker for detection of oral cancer.

備註

本部(收文號1100069253)同意該校110年11月16日長庚大字第1100110241號函申請終止維護專利(長庚)

連絡單位 (專責單位/部門名稱)

技術移轉中心

連絡電話

03-2118800轉3201

網址